Unknown

Dataset Information

0

Randomized immunotherapy trial in dual-allergic patients using "active allergen placebo" as control.


ABSTRACT: BACKGROUND:Placebo control in allergen immunotherapy (AIT) trials presents ethical and blinding concerns. We tested a trial design with an "active allergen placebo," as proposed by ARIA-GA2 LEN, to investigate in a double-blind trial the efficacy and safety of AIT in dual-allergic patients (grass and birch pollen) using active untargeted treatments as controls. METHODS:We randomized 95 patients to receive either grass (N = 47) or birch AIT (N = 48). Patients were exposed to both allergens in an allergen challenge chamber (ACC) before and after 9 months of AIT. Targeted (ACC-allergen = AIT-allergen) and untargeted (ACC-allergen ≠ AIT-allergen) treatment effects were assessed. RESULTS:Immunotherapy reduced significantly the mean (95% confidence interval) area under the curve of total nasal symptom score (targeted effects) by -13.55 (-17.56, -9.54; P < 0.001) after grass and -9.81 (-14.13, -5.50; P < 0.001) after birch AIT. Differences in targeted vs untargeted effects between AIT groups (utility of control group) were statistically significant for both grass (P = 0.02) and birch (P = 0.02) allergens. Targeted vs untargeted differences within-treatment groups (specificity of ACC measurement) were significant for grass AIT (P < 0.001) but not significant for birch AIT group (P = 0.24). Specific immunoglobulin G4 to both allergens increased significantly (P < 0.001) after targeted treatment, while remained unchanged for untargeted treatments. Both treatments were well tolerated. CONCLUSIONS:Immunotherapies for both grass and birch allergens were efficacious and safe. The study confirms the specificity of AIT. Untargeted treatment groups could serve as controls in future AIT trials.

SUBMITTER: Wagenmann M 

PROVIDER: S-EPMC6773203 | biostudies-other | 2019 Aug

REPOSITORIES: biostudies-other

altmetric image

Publications

Randomized immunotherapy trial in dual-allergic patients using "active allergen placebo" as control.

Wagenmann Martin M   Worm Margitta M   Akboga Yasemin Y   Karjalainen Martin M   Hohlfeld Jens M JM  

Allergy 20190528 8


<h4>Background</h4>Placebo control in allergen immunotherapy (AIT) trials presents ethical and blinding concerns. We tested a trial design with an "active allergen placebo," as proposed by ARIA-GA<sup>2</sup> LEN, to investigate in a double-blind trial the efficacy and safety of AIT in dual-allergic patients (grass and birch pollen) using active untargeted treatments as controls.<h4>Methods</h4>We randomized 95 patients to receive either grass (N = 47) or birch AIT (N = 48). Patients were expose  ...[more]

Similar Datasets

| S-EPMC5994829 | biostudies-literature
| S-EPMC6175232 | biostudies-literature
| S-EPMC4746770 | biostudies-other
| S-EPMC10161758 | biostudies-literature
| S-EPMC5539638 | biostudies-other
| S-EPMC4694090 | biostudies-other
| S-EPMC5947135 | biostudies-other
| S-EPMC5547534 | biostudies-literature
| S-EPMC9709690 | biostudies-literature
| S-EPMC2582048 | biostudies-literature